세계의 체외 전사 템플릿 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

In-vitro Transcription Templates Market - Scope of Report

TMR's report on the global in-vitro transcription templates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global in-vitro transcription templates market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global in-vitro transcription templates market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the in-vitro transcription templates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global in-vitro transcription templates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global in-vitro transcription templates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global in-vitro transcription templates market.

The report delves into the competitive landscape of the global in-vitro transcription templates market. Key players operating in the global in-vitro transcription templates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global in-vitro transcription templates market profiled in this report.

Key Questions Answered in Global in-vitro transcription templates Market Report:

• What is the sales/revenue generated by in-vitro transcription templates across all regions during the forecast period?
• What are the opportunities in the global in-vitro transcription templates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

In-vitro Transcription Templates Market - Research Objectives and Research Approach

The comprehensive report on the global in-vitro transcription templates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global in-vitro transcription templates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global in-vitro transcription templates market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global In-vitro Transcription Templates Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global In-vitro Transcription Templates Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global In-vitro Transcription Templates Market Analysis and Forecast, by Disease

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Disease, 2017-2031
  • 6.3.1. Cancer
    • 6.3.1.1. Solid Tumors
    • 6.3.1.2. Colorectal Cancer
    • 6.3.1.3. NSCLC
    • 6.3.1.4. Melanoma
    • 6.3.1.5. Leukemia
    • 6.3.1.6. Prostate Cancer
    • 6.3.1.7. Others
  • 6.3.2. Infectious Diseases
    • 6.3.2.1. Influenza
    • 6.3.2.2. COVID-19
    • 6.3.2.3. AIDS
    • 6.3.2.4. Others
  • 6.3.3. Lifestyle Diseases
  • 6.3.4. Genetic Diseases
  • 6.3.5. Others
• 6.4. Market Attractiveness, by Disease

7. Global In-vitro Transcription Templates Market Analysis and Forecast, by Treatment

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Treatment, 2017-2031
  • 7.3.1. Vaccine
  • 7.3.2. Therapeutic
  • 7.3.3. 7.4 Market Attractiveness, by Treatment

8. Global In-vitro Transcription Templates Market Analysis and Forecast, by Research Stage

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Research Stage, 2017-2031
  • 8.3.1. Exploratory
  • 8.3.2. Clinical
• 8.4. Market Attractiveness, by Research Stage

9. Global In-vitro Transcription Templates Market Analysis and Forecast, by End-user

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Pharmaceutical & Biotechnology Companies
  • 9.3.2. CROs & CMOs
  • 9.3.3. Academics & Research
  • 9.3.4. Others
• 9.4. Market Attractiveness, by End-user

10. Global In-vitro Transcription Templates Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness, by Region

11. North America In-vitro Transcription Templates Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Disease, 2017-2031
  • 11.2.1. Cancer
    • 11.2.1.1. Solid Tumors
    • 11.2.1.2. Colorectal Cancer
    • 11.2.1.3. NSCLC
    • 11.2.1.4. Melanoma
    • 11.2.1.5. Leukemia
    • 11.2.1.6. Prostate Cancer
    • 11.2.1.7. Others
  • 11.2.2. Infectious Diseases
    • 11.2.2.1. Influenza
    • 11.2.2.2. COVID-19
    • 11.2.2.3. AIDS
    • 11.2.2.4. Others
  • 11.2.3. Lifestyle Diseases
  • 11.2.4. Genetic Diseases
  • 11.2.5. Others
• 11.3. Market Attractiveness, by Disease
• 11.4. Market Value Forecast, by Treatment, 2017-2031
  • 11.4.1. Vaccine
  • 11.4.2. Therapeutic
• 11.5. Market Attractiveness, by Treatment
• 11.6. Market Value Forecast, by Research Stage, 2017-2031
  • 11.6.1. Exploratory
  • 11.6.2. Clinical
• 11.7. Market Attractiveness, by Research Stage
• 11.8. Market Value Forecast, by End-user, 2017-2031
  • 11.8.1. Pharmaceutical & Biotechnology Companies
  • 11.8.2. CROs & CMOs
  • 11.8.3. Academics & Research
  • 11.8.4. Others
• 11.9. Market Attractiveness, by End-user
• 11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.10.1. U.S.
  • 11.10.2. Canada
• 11.11. Market Attractiveness Analysis
  • 11.11.1. By Disease
  • 11.11.2. By Treatment
  • 11.11.3. By Research Stage
  • 11.11.4. By End-user
  • 11.11.5. By Country

12. Europe In-vitro Transcription Templates Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Disease, 2017-2031
  • 12.2.1. Cancer
    • 12.2.1.1. Solid Tumors
    • 12.2.1.2. Colorectal Cancer
    • 12.2.1.3. NSCLC
    • 12.2.1.4. Melanoma
    • 12.2.1.5. Leukemia
    • 12.2.1.6. Prostate Cancer
    • 12.2.1.7. Others
  • 12.2.2. Infectious Diseases
    • 12.2.2.1. Influenza
    • 12.2.2.2. COVID-19
    • 12.2.2.3. AIDS
    • 12.2.2.4. Others
  • 12.2.3. Lifestyle Diseases
  • 12.2.4. Genetic Diseases
  • 12.2.5. Others
• 12.3. Market Attractiveness, by Disease
• 12.4. Market Value Forecast, by Treatment, 2017-2031
  • 12.4.1. Vaccine
  • 12.4.2. Therapeutic
• 12.5. Market Attractiveness, by Treatment
• 12.6. Market Value Forecast, by Research Stage, 2017-2031
  • 12.6.1. Exploratory
  • 12.6.2. Clinical
• 12.7. Market Attractiveness, by Research Stage
• 12.8. Market Value Forecast, by End-user, 2017-2031
  • 12.8.1. Pharmaceutical & Biotechnology Companies
  • 12.8.2. CROs & CMOs
  • 12.8.3. Academics & Research
  • 12.8.4. Others
• 12.9. Market Attractiveness, by End-user
• 12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.10.1. Germany
  • 12.10.2. U.K.
  • 12.10.3. France
  • 12.10.4. Italy
  • 12.10.5. Spain
  • 12.10.6. Rest of Europe
• 12.11. Market Attractiveness Analysis
  • 12.11.1. By Disease
  • 12.11.2. By Treatment
  • 12.11.3. By Research Stage
  • 12.11.4. By End-user
  • 12.11.5. By Country/Sub-region

13. Asia Pacific In-vitro Transcription Templates Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Disease, 2017-2031
  • 13.2.1. Cancer
    • 13.2.1.1. Solid Tumors
    • 13.2.1.2. Colorectal Cancer
    • 13.2.1.3. NSCLC
    • 13.2.1.4. Melanoma
    • 13.2.1.5. Leukemia
    • 13.2.1.6. Prostate Cancer
    • 13.2.1.7. Others
  • 13.2.2. Infectious Diseases
    • 13.2.2.1. Influenza
    • 13.2.2.2. COVID-19
    • 13.2.2.3. AIDS
    • 13.2.2.4. Others
  • 13.2.3. Lifestyle Diseases
  • 13.2.4. Genetic Diseases
  • 13.2.5. Others
• 13.3. Market Attractiveness, by Disease
• 13.4. Market Value Forecast, by Treatment, 2017-2031
  • 13.4.1. Vaccine
  • 13.4.2. Therapeutic
• 13.5. Market Attractiveness, by Treatment
• 13.6. Market Value Forecast, by Research Stage, 2017-2031
  • 13.6.1. Exploratory
  • 13.6.2. Clinical
• 13.7. Market Attractiveness, by Research Stage
• 13.8. Market Value Forecast, by End-user, 2017-2031
  • 13.8.1. Pharmaceutical & Biotechnology Companies
  • 13.8.2. CROs & CMOs
  • 13.8.3. Academics & Research
  • 13.8.4. Others
• 13.9. Market Attractiveness, by End-user
• 13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.10.1. China
  • 13.10.2. Japan
  • 13.10.3. India
  • 13.10.4. Australia & New Zealand
  • 13.10.5. Rest of Asia Pacific
• 13.11. Market Attractiveness Analysis
  • 13.11.1. By Disease
  • 13.11.2. By Treatment
  • 13.11.3. By Research Stage
  • 13.11.4. By End-user
  • 13.11.5. By Country/Sub-region

14. Latin America In-vitro Transcription Templates Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Disease, 2017-2031
  • 14.2.1. Cancer
    • 14.2.1.1. Solid Tumors
    • 14.2.1.2. Colorectal Cancer
    • 14.2.1.3. NSCLC
    • 14.2.1.4. Melanoma
    • 14.2.1.5. Leukemia
    • 14.2.1.6. Prostate Cancer
    • 14.2.1.7. Others
  • 14.2.2. Infectious Diseases
    • 14.2.2.1. Influenza
    • 14.2.2.2. COVID-19
    • 14.2.2.3. AIDS
    • 14.2.2.4. Others
  • 14.2.3. Lifestyle Diseases
  • 14.2.4. Genetic Diseases
  • 14.2.5. Others
• 14.3. Market Attractiveness, by Disease
• 14.4. Market Value Forecast, by Treatment, 2017-2031
  • 14.4.1. Vaccine
  • 14.4.2. Therapeutic
• 14.5. Market Attractiveness, by Treatment
• 14.6. Market Value Forecast, by Research Stage, 2017-2031
  • 14.6.1. Exploratory
  • 14.6.2. Clinical
• 14.7. Market Attractiveness, by Research Stage
• 14.8. Market Value Forecast, by End-user, 2017-2031
  • 14.8.1. Pharmaceutical & Biotechnology Companies
  • 14.8.2. CROs & CMOs
  • 14.8.3. Academics & Research
  • 14.8.4. Others
• 14.9. Market Attractiveness, by End-user
• 14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.10.1. Brazil
  • 14.10.2. Mexico
  • 14.10.3. Rest of Latin America
• 14.11. Market Attractiveness Analysis
  • 14.11.1. By Disease
  • 14.11.2. By Treatment
  • 14.11.3. By Research Stage
  • 14.11.4. By End-user
  • 14.11.5. By Country/Sub-region

15. Middle East & Africa In-vitro Transcription Templates Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Disease, 2017-2031
  • 15.2.1. Cancer
    • 15.2.1.1. Solid Tumors
    • 15.2.1.2. Colorectal Cancer
    • 15.2.1.3. NSCLC
    • 15.2.1.4. Melanoma
    • 15.2.1.5. Leukemia
    • 15.2.1.6. Prostate Cancer
    • 15.2.1.7. Others
  • 15.2.2. Infectious Diseases
    • 15.2.2.1. Influenza
    • 15.2.2.2. COVID-19
    • 15.2.2.3. AIDS
    • 15.2.2.4. Others
  • 15.2.3. Lifestyle Diseases
  • 15.2.4. Genetic Diseases
  • 15.2.5. Others
• 15.3. Market Attractiveness, by Disease
• 15.4. Market Value Forecast, by Treatment, 2017-2031
  • 15.4.1. Vaccine
  • 15.4.2. Therapeutic
• 15.5. Market Attractiveness, by Treatment
• 15.6. Market Value Forecast, by Research Stage, 2017-2031
  • 15.6.1. Exploratory
  • 15.6.2. Clinical
• 15.7. Market Attractiveness, by Research Stage
• 15.8. Market Value Forecast, by End-user, 2017-2031
  • 15.8.1. Pharmaceutical & Biotechnology Companies
  • 15.8.2. CROs & CMOs
  • 15.8.3. Academics & Research
  • 15.8.4. Others
• 15.9. Market Attractiveness, by End-user
• 15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.10.1. GCC Countries
  • 15.10.2. South Africa
  • 15.10.3. Rest of Middle East & Africa
• 15.11. Market Attractiveness Analysis
  • 15.11.1. By Disease
  • 15.11.2. By Treatment
  • 15.11.3. By Research Stage
  • 15.11.4. By End-user
  • 15.11.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2022)
• 16.3. Company Profiles
  • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Promega Corporation
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. Agilent Technologies, Inc.
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. New England Biolabs
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Takara Bio Inc.
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. LGC Limited
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Enzynomics Co. Ltd.
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Enzo Life Sciences, Inc.
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Danaher Corporation
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview